Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYPENZA: Antiandrogen Effects on Dexamethasone Pharmacokinetics
2025-520571-66-00Phase 3Authorised
- Sponsor
- Region Västerbotten
- Start
- Feb 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of enzalutamide, apalutamide and dexamethasone in prostate cancer (PCa) (2 cohorts), sponsored by Region Västerbotten. Planned start Feb 2026; status: authorised.
02
Drugs
enzalutamideapalutamidedexamethasone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2025-520571-66-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520571-66-00.